Upadacitinib improved symptoms, QoL in moderate-to-severe AD
16 Dec 2020
byRoshini Claire Anthony
Upadacitinib monotherapy improved symptoms and quality of life (QoL) in adolescents and adults with moderate-to-severe atopic dermatitis (AD), according to the phase III Measure Up 1 and 2 studies presented at EADV 2020.
Upadacitinib improved symptoms, QoL in moderate-to-severe AD
16 Dec 2020
